Kura Oncology (KURA) Return on Capital Employed (2011 - 2026)
Kura Oncology (KURA) posted quarterly Return on Capital Employed of 46.14% for Q1 2026, down 4396.0% year-over-year from 1.07% in Q1 2025, and down 2.4% quarter-over-quarter from 45.06% in Q4 2025.
Kura Oncology (KURA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Return on Capital Employed for 7 consecutive years, with 46.14% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 4396.0% year-over-year to 46.14%; the TTM figure through Mar 2026 stood at 46.14% (down 4396.0% YoY), while the FY2025 annual figure was 48.02%, down 1128.0% from the prior year.
- Return on Capital Employed eased to 46.14% in Q1 2026 per KURA's latest filing, from 45.06% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 0.22% in Q4 2024 and bottomed at 46.14% in Q1 2026.
- Historically, Return on Capital Employed has averaged 18.05% across 3 years, with a median of 10.45% in 2024.
- On a YoY basis, Return on Capital Employed climbed as much as 2903 bps in 2025 and fell as far as 4528 bps in 2025.
- Kura Oncology's Return on Capital Employed stood at 0.22% in 2024, then tumbled by 20272 bps to 45.06% in 2025, then declined by 2 bps to 46.14% in 2026.
- Business Quant data shows KURA's Return on Capital Employed at 46.14% in Q1 2026, 45.06% in Q4 2025, and 4.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | -60.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.73% |
| Mar 31, 2026 | -46.14% |
| Dec 31, 2025 | -45.06% |
| Sep 30, 2025 | -4.56% |
| Jun 30, 2025 | -0.86% |
| Mar 31, 2025 | -2.18% |
| Dec 31, 2024 | 0.22% |
| Sep 30, 2024 | -33.59% |
| Jun 30, 2024 | -19.83% |
| Mar 31, 2024 | -10.45% |
| Dec 31, 2014 | 1.03% |
| Mar 31, 2013 | 23.00% |
| Dec 31, 2012 | 23.83% |
| Sep 30, 2012 | 26.26% |
| Jun 30, 2012 | 29.96% |
| Mar 31, 2012 | 28.47% |
| Dec 31, 2011 | 35.45% |
| Sep 30, 2011 | 40.02% |
| Jun 30, 2011 | 37.64% |